| 27/03/26 | 08:00:00 | 27 Mar 2026 | | Readmission - Roquefort Therapeutics Plc |
| 26/03/26 | 13:00:01 | 26 Mar 2026 | | Investor Presentation |
| 26/03/26 | 12:08:49 | 26 Mar 2026 | | Result of General Meeting |
| 25/03/26 | 07:00:09 | 25 Mar 2026 | | Lyramid SPA & MK Cell License Update |
| 02/03/26 | 08:00:00 | 2 Mar 2026 | | Schedule One - Roquefort Therapeutics PLC |
| 02/03/26 | 07:00:11 | 2 Mar 2026 | | Proposed Acquisition and Fundraise of £8.5 million |
| 25/02/26 | 07:00:10 | 25 Feb 2026 | | Transaction Update & Notice of Intention to Delist |
| 15/01/26 | 07:00:10 | 15 Jan 2026 | | Research Note Published |
| 12/12/25 | 07:00:06 | 12 Dec 2025 | | Clinical Trial & License Agreement Update |
| 09/12/25 | 07:00:04 | 9 Dec 2025 | | Conversion of CLNs |
| 01/12/25 | 10:35:41 | 1 Dec 2025 | | Ex-Entitlement Date - Unlisted RNV Shares |
| 01/12/25 | 07:00:13 | 1 Dec 2025 | | Determination of Record Date and Entitlement |
| 25/11/25 | 07:00:20 | 25 Nov 2025 | | Holding(s) in Company |
| 24/11/25 | 07:00:11 | 24 Nov 2025 | | Director/PDMR Shareholding |
| 18/11/25 | 07:00:09 | 18 Nov 2025 | | Executed License Agreement & Transaction Update |
| 03/11/25 | 07:00:12 | 3 Nov 2025 | | MK Cell Out-License & Lyramid SPA Update |
| 16/10/25 | 07:00:02 | 16 Oct 2025 | | Fundraise & Transaction Update |
| 30/09/25 | 07:00:04 | 30 Sept 2025 | | Interim Results to 30 June 2025 |
| 24/09/25 | 07:00:15 | 24 Sept 2025 | | Investor Presentation via Engage Investor |
| 08/09/25 | 07:00:09 | 8 Sept 2025 | | Proposed Acquisition of Clinical Stage Company |
| 28/08/25 | 07:00:02 | 28 Aug 2025 | | Lyramid SPA 2nd Extension & Carve Out |
| 07/07/25 | 07:00:09 | 7 Jul 2025 | | Director/PDMR Shareholding |
| 30/06/25 | 07:00:14 | 30 Jun 2025 | | Director/PDMR Shareholding |
| 27/06/25 | 07:00:05 | 27 Jun 2025 | | Lyramid SPA Extension |
| 26/06/25 | 13:00:01 | 26 Jun 2025 | | Results of AGM |
| 13/06/25 | 16:00:01 | 13 Jun 2025 | | Issue of Equity |
| 02/06/25 | 07:00:14 | 2 Jun 2025 | | Notice of Annual General Meeting |
| 23/05/25 | 07:00:07 | 23 May 2025 | | Extension of Convertible Loan Notes |
| 13/05/25 | 07:00:04 | 13 May 2025 | | Corporate Update |
| 30/04/25 | 07:00:09 | 30 Apr 2025 | | Annual Report & Financial Statements - 31 Dec 2024 |
| 14/03/25 | 07:00:07 | 14 Mar 2025 | | Private Placing and Conversion of CLNs |
| 10/03/25 | 07:30:00 | 10 Mar 2025 | | Board Changes |
| 10/03/25 | 07:00:11 | 10 Mar 2025 | | Proposed Sale of Oncogeni Ltd |
| 04/03/25 | 07:00:10 | 4 Mar 2025 | | Update on Sale of Lyramid |
| 04/02/25 | 10:58:22 | 4 Feb 2025 | | Director/PDMR Shareholding |
| 03/02/25 | 07:00:07 | 3 Feb 2025 | | Share Purchase Agreement Signed - Sale of Lyramid |
| 02/01/25 | 07:00:06 | 2 Jan 2025 | | Proposed Sale of Midkine Portfolio |
| 04/12/24 | 16:00:00 | 4 Dec 2024 | | Director Share Distribution |
| 07/11/24 | 07:00:05 | 7 Nov 2024 | | Conversion of Convertible Loan Notes |
| 06/11/24 | 07:00:08 | 6 Nov 2024 | | STAT-6 siRNA Presentation |
| 27/09/24 | 07:00:01 | 27 Sept 2024 | | Interim Results to 30 June 2024 |
| 23/09/24 | 07:00:07 | 23 Sept 2024 | | Grant of Japan MK Cell Patent |
| 19/09/24 | 07:00:02 | 19 Sept 2024 | | STAT-6 siRNA Demonstrates Efficacy in Immunology |
| 02/09/24 | 07:00:08 | 2 Sept 2024 | | Grant of MK Cell Patent & Licencing Update |
| 27/06/24 | 12:46:12 | 27 Jun 2024 | | Results of AGM |
| 20/06/24 | 07:00:10 | 20 Jun 2024 | | Appointment of Broker |
| 04/06/24 | 07:00:09 | 4 Jun 2024 | | Notice of Annual General Meeting |
| 23/05/24 | 07:05:00 | 23 May 2024 | | Issue of Convertible Loan Notes & Board Changes |
| 23/05/24 | 07:00:15 | 23 May 2024 | | Midkine Antibody Licencing Deal |
| 26/04/24 | 07:00:10 | 26 Apr 2024 | | Annual Report & Financial Statements - 31 Dec 2023 |
